Finzati - Logo
CORT logo

Corcept Therapeutics Incorporated

CORT • Medical - Pharmaceuticals
$111.62
▼ -1.18 (-1.05%)
Current price
EarningsLatest report: Jun 30, 2026
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$12.70B
Growth
—
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 13.1%Positive revenue growth · 23.4%Positive free cash flow · 1.37Consistent free cash flow · 5/5Manageable debt level · 0.01
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$111.62
Change-1.05%
Market Cap$12.70B
52W Range28.66 - 122.21
Beta0.46
Gross Margin98.30%
Oper. Margin5.88%
Profit Margin13.09%
Debt/Eq0.01
Current Ratio2.92
Quick Ratio2.85
Target$117.60

Investment DNA

How strong this company looks for long-term investors

62
out of 100
Business Quality
Margins, moat, returns
48/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
59/100
Price Attractiveness
Cheap or expensive today
45/100
Why this score▼
Stable or improving margins · 13.1%Positive revenue growth · 23.4%Positive free cash flow · 1.37Consistent free cash flow · 5/5Manageable debt level · 0.01Healthy liquidity · 2.92

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-07-31
Low
$50.00
Mean
$117.60
Median
$135.00
High
$165.00

Company Overview

IPO: 4/14/2004
Industry: Medical - Pharmaceuticals
P/B i: 5.58
Debt / Equity i: 0.01
Operating Margin: 5.88%
Net Margin: 13.09%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.01
Current Ratio: 2.92
Quick Ratio: 2.85
Status: Good

Insider Transactions

Recent executive and insider activity

Mokari Atabak
Transaction: 07/15/2026
SELL
Change
-101
Price
$89.43
Filing
07/17/2026
Type
SELL
Mokari Atabak
Transaction: 07/15/2026
SELL
Change
-15,833
Price
$19.26
Filing
07/17/2026
Type
SELL
WILSON JAMES N
Transaction: 07/15/2026
SELL
Change
-1,978
Price
$89.49
Filing
07/17/2026
Type
SELL